NCT06959641 - XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

September 11, 2028

Study Completion Date

September 11, 2030

Conditions

Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular CarcinomaLocally Advanced Thyroid Gland Oncocytic CarcinomaLocally Advanced Thyroid Gland Papillary CarcinomaMetastatic Differentiated Thyroid Gland CarcinomaMetastatic Poorly Differentiated Thyroid Gland CarcinomaMetastatic Thyroid Gland Follicular CarcinomaMetastatic Thyroid Gland Oncocytic CarcinomaMetastatic Thyroid Gland Papillary CarcinomaRefractory Differentiated Thyroid Gland CarcinomaRefractory Poorly Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Oncocytic CarcinomaRefractory Thyroid Gland Papillary CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Thyroid Gland Follicular Carcinoma AJCC v8Stage III Thyroid Gland Papillary Carcinoma AJCC v8Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8Stage IV Thyroid Gland Follicular Carcinoma AJCC v8Stage IV Thyroid Gland Papillary Carcinoma AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Survey Administration

Ancillary studies

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

DRUG

Zanzalintinib

Given PO

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER